• Miscellaneous Ob/Gyn conditions

Vyleesi Generic Name & Formulations

General Description

Bremelanotide acetate 1.75mg/0.3mL; soln for SC inj.

Pharmacological Class

Melanocortin receptor agonist.

How Supplied

Single-dose prefilled autoinjectors—4

Generic Availability


Vyleesi Indications


Acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women and is not due to a coexisting medical or psychiatric condition, problems within the relationship, or adverse effect of a medication or other drug substance.

Limitations of Use

Not for HSDD in postmenopausal women or in men. Not for sexual performance enhancement.

Vyleesi Dosage and Administration


Give by SC inj in abdomen or thigh as needed, at least 45mins before sexual activity. 1.75mg as a single daily dose. Max 1 dose per 24hrs or 8 doses per month. Discontinue if no improvement after 8 weeks.


Not established.

Vyleesi Contraindications


Uncontrolled hypertension. Known cardiovascular disease.

Vyleesi Boxed Warnings

Not Applicable

Vyleesi Warnings/Precautions


Consider patient’s cardiovascular risk before initiating and periodically during treatment, and ensure BP is well-controlled. High risk for cardiovascular disease: not recommended. Consider discontinuing if hyperpigmentation develops. Severe hepatic or renal impairment. Pregnancy: not recommended; discontinue if suspected. Nursing mothers.

Vyleesi Pharmacokinetics

See Literature

Vyleesi Interactions


Avoid concomitant oral drugs that depend on threshold concentrations for efficacy (eg, antibiotics). Consider discontinuing if there is a delayed effect of concomitant oral drug when a quick onset is desired (eg, indomethacin). Avoid use with oral naltrexone-containing products intended to treat alcohol or opioid addiction.

Vyleesi Adverse Reactions

Adverse Reactions

Nausea, flushing, inj site reactions, headache, vomiting, cough, fatigue, hot flush, paraesthesia, dizziness, nasal congestion; focal hyperpigmentation (esp. with dark skin), transient increases in BP and reduction in HR.

Vyleesi Clinical Trials

See Literature

Vyleesi Note

Not Applicable

Vyleesi Patient Counseling

See Literature